Business

Mass. mover

Alnylam Pharmaceuticals settles legal battle

Alnylam and Tekmira entered a settlement.

istockphoto.com

Alnylam and Tekmira entered a settlement.

Advertisement

Alnylam Pharmaceuticals Inc., a Cambridge company looking to develop therapeutics based on RNA interference, said it has restructured its relationship with Tekmira Pharmaceuticals with a new licensing agreement. It also said the companies have resolved all litigation between them. Tekmira will receive $65 million, and is eligible to receive $10 million in near-term milestone payments. The litigation involved intellectual property rights of lipid nanoparticle technology, Tekmira said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com